Journal ArticleOPEN ACCESS

Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review

Clinical Case Reports (2021) 9(5)
DOI: 10.1002/ccr3.3164
3Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.

Author supplied keywords

Cite

CITATION STYLE

APA

Liu, Q., Ass’ad, N. A., & Arana Yi, C. (2021). Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review. Clinical Case Reports, 9(5). https://doi.org/10.1002/ccr3.3164

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free